贝伐单抗联合放疗方案通过调节VEGF/VEGFR2信号传导治疗NSCLC患者的系统评价

doi:10.5246/jcps.2024.12.083

中国药学(英文版) ›› 2024, Vol. 33 ›› Issue (12): 1137-1145.DOI: 10.5246/jcps.2024.12.083

贝伐单抗联合放疗方案通过调节VEGF/VEGFR2信号传导治疗NSCLC患者的系统评价

宋张鹏¹, 周锋¹, 张杨勇¹, 张洁², 冯媛¹^,^*()

^1. 延安大学咸阳医院, 陕西咸阳 712000
^2. 陕西中医药大学第一附属医院, 陕西咸阳 712000

收稿日期:2024-04-13 修回日期:2024-05-21 接受日期:2024-07-13 出版日期:2025-01-07 发布日期:2025-01-06
通讯作者: 冯媛

Systematic review: bevacizumab combined with radiotherapy regimen in NSCLC patients, modulating VEGF/VEGFR2 signaling

Zhangpeng Song¹, Feng Zhou¹, Yangyong Zhang¹, Jie Zhang², Yuan Feng¹^,^*()

¹ Xianyang Hospital of Yan’an University, Xianyang 712000, Shaanxi, China
² The First Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, China

Received:2024-04-13 Revised:2024-05-21 Accepted:2024-07-13 Online:2025-01-07 Published:2025-01-06
Contact: Yuan Feng

摘要/Abstract

摘要：

探讨贝伐单抗联合放疗与单独使用放疗治疗方案相比对NSCLC患者的疗效以及对抗肿瘤新生血管生成作用的影响, 同时评估治疗后NSCLC患者生活质量和预后。回顾性分析2020年1月–2021年1月在我院肿瘤科就诊治疗的100例NSCLC患者为研究对象, 对照组(n = 50)采用放疗手段进行保守治疗, 观察组(n = 50)采用贝伐珠单抗联合放疗治疗。根据患者档案统计临床信息, ELISA检测血清VEGF及VEGFR的表达水平。根据疗效评定标准分析两组患者治疗效果。使用肺癌症状量表和肺癌症治疗功能评估衡量贝伐单抗联合放疗对患者生活质量的影响, 同时对患者进行两年随访并分析生存率。结果显示观察组血清VEGF、VEGFR1和VEGFR2水平较对照组降低(P < 0.05)。观察组完全缓解率、部分缓解率和疾病控制率较对照组升高(P < 0.05), 观察组疾病进展率较对照组降低(P < 0.05)。观察组LCSS评分较对照组降低(P < 0.05), 观察组FACT-L和综合评分TOI较对照组升高(P < 0.05), 观察组生活质量较对照组升高(P < 0.05)。6个月时, 两组患者生存率比较无差异(P > 0.05), 12个月、18个月和24个月时, 观察组生存率较对照组升高(P < 0.05)。观察组中位生存期为20个月, 对照组中位生存期为15个月, 观察组中位生存时间较对照组延长(P < 0.05)。研究表明贝伐单抗联合放疗方案可下调NSCLC患者体内VEGF、VEGFR的表达, 对抗肿瘤新生血管生成, 改善NSCLC患者生存质量, 延长生命期限。

关键词: 贝伐珠单抗联合放疗, NSCLC, VEGF, VEGFR, 临床效果

Abstract:

To assess the efficacy of radiotherapy combined with bevacizumab compared to radiotherapy alone in patients with non-small cell lung cancer (NSCLC) and to explore its impact on anti-tumor neovascularization, we conducted a retrospective analysis of 100 NSCLC patients treated in the oncology department of our hospital from January 2020 to January 2021. The control group (n = 50) received conservative treatment with chemotherapy, while the observation group (n = 50) underwent treatment with bevacizumab combined with radiotherapy. Clinical data were collected from patient records. Levels of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in serum were measured using enzyme-linked immunosorbent assay (ELISA). The therapeutic outcomes of both groups were assessed based on established evaluation criteria. The Lung Cancer Symptom Scale and Lung Cancer Treatment Function were utilized to evaluate patients’ quality of life. Patients were followed up for 2 years, and survival rates were analyzed. Our findings revealed that serum levels of VEGF, VEGFR1, and VEGFR2 in the observation group were significantly lower than those in the control group (P < 0.05). Additionally, the observation group exhibited higher rates of complete response, partial response, and disease control compared to the control group (P < 0.05), along with a lower rate of disease progression (P < 0.05). The Lung Cancer Symptom Scale score was lower in the observation group compared to the control group (P < 0.05), while the Functional Assessment of Cancer Therapy-Lung (FACT-L) score and Total Outcome Index (TOI) were higher (P < 0.05), indicating a superior quality of life in the observation group. At 6 months, there was no significant difference in survival rates between the two groups (P > 0.05); however, at 12, 18, and 24 months, the observation group demonstrated higher survival rates than the control group (P < 0.05). The median survival time of the observation group (20 months) was significantly longer than that of the control group (15 months, P < 0.05). In conclusion, the combination of bevacizumab and radiotherapy led to the down-regulation of VEGF and VEGFR expression in NSCLC patients, thereby inhibiting tumor angiogenesis, enhancing patient quality of life, and prolonging overall survival.

Key words: one, Bevacizumab combined with radiotherapy, NSCLC, VEGF, VEGFR, Clinical effect

Supporting:

宋张鹏, 周锋, 张杨勇, 张洁, 冯媛. 贝伐单抗联合放疗方案通过调节VEGF/VEGFR2信号传导治疗NSCLC患者的系统评价[J]. 中国药学(英文版), 2024, 33(12): 1137-1145.

Zhangpeng Song, Feng Zhou, Yangyong Zhang, Jie Zhang, Yuan Feng. Systematic review: bevacizumab combined with radiotherapy regimen in NSCLC patients, modulating VEGF/VEGFR2 signaling[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(12): 1137-1145.

图/表 6

Table 1. Clinical data statistics of patients (x ± s).

Table 2. Analysis of serum VEGF and VEGFR levels (x ± s, pg/mL).

Table 3. Clinical treatment effect analysis (x ± s, %).

Table 4. HRQOL analysis of quality of life (x ± s, %).

Figure 1. Analysis of 2-year survival rate of patients.

Table 5. Analysis of 2-year survival rate of patients (x ± s, %).

参考文献 20

[1]	Chen, W.T.; Chen, C.H.; Su, H.T.; Yueh, P.F.; Hsu, F.T.; Chiang, I.T. Amentoflavone induces cell-cycle arrest, apoptosis, and invasion inhibition in non-small cell lung cancer cells. Anticancer Res. 2021, 41, 1357–1364.
[2]	Shi, Y.F.; Lei, Y.M.; Liu, L.; Zhang, S.Y.; Wang, W.J.; Zhao, J.; Zhao, S.H.; Dong, X.W.; Yao, M.; Wang, K.; Zhou, Q. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021, 10, 2216–2231.
[3]	Wang, S.; Yu, H.; Gan, Y.C.; Wu, Z.J.; Li, E.C.; Li, X.H.; Cao, J.X.; Zhu, Y.B.; Wang, L.S.; Deng, H.; Xie, M.; Wang, Y.Y.; Ma, X.D.; Liu, D.; Chen, B.J.; Tian, P.W.; Qiu, Z.X.; Xian, J.H.; Ren, J.; Wang, K.; Wei, W.; Xie, F.; Li, Z.H.; Wang, Q.; Xue, X.Y.; Liu, Z.Y.; Shi, J.Y.; Li, W.M.; Tian, J. Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. Lancet Digit. Health. 2022, 4, e309–e319.
[4]	Lurienne, L.; Cervesi, J.; Duhalde, L.; de Gunzburg, J.; Andremont, A.; Zalcman, G.; Buffet, R.; Bandinelli, P.A. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J. Thorac. Oncol. 2020, 15, 1147–1159.
[5]	Fu, Y.N.; Wang, G.M.; Chen, Q. The effect of bevacizumab combined with concurrent radiotherapy and chemotherapy combined with metformin on the efficacy, immune function, and tumor-related proteins in non-small cell lung cancer patients. J. Xuzhou Med. Coll. 2021, 41, 693–698.
[6]	Li, J.; Gao, A.Q.; Zhang, F.; Wang, S.Y.; Wang, J.N.; Wang, J.; Han, S.Y.; Yang, Z.J.; Chen, X.Z.; Fang, Y.Y.; Jiang, G.S.; Sun, Y.P. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. Cancer Lett. 2021, 501, 263–276.
[7]	Liu, Y.G.; Xiao, A.L.; Zhang, B.Y. CCR10/CCL27 crosstalk regulates cell metastasis via PI3K-Akt signaling axis in non-small-cell lung cancer. Am. J. Transl. Res. 2021, 13, 13135–13146.
[8]	Song, Z.J. Clinical efficacy of bevacizumab combined with pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer. Chin. Foreign Med. Res. 2021, 19, 46–48.
[9]	Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567–578.
[10]	Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011–1027.
[11]	Shibuya, M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011, 2, 1097–1105.
[12]	Nagano, T.; Tachihara, M.; Nishimura, Y. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Curr. Cancer Drug Targets. 2019, 19, 595–630.
[13]	Puri, S.; Chatwal, M.; Gray, J.E. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Exp. Rev. Respir. Med. 2017, 11, 791–805.
[14]	Ruan, T.Y.; Jiang, L.P.; Xu, J.Y.; Zhou, J.Y. Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells. J. Bioenerg. Biomembr. 2021, 53, 343–349.
[15]	Liu, N. The effect of bevacizumab combined with paclitaxel and cisplatin on serum tumor markers in non-small cell lung cancer patients. Shanxi Med. J. 2020, 49, 2974–2976.
[16]	Tian, Y.R.; Tian, H.R.; Zhai, X.Y.; Zhu, H.; Yu, J.M. Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis. Front. Med. 2022, 16, 610–617.
[17]	Tsutsumi, K.; Chiba, A.; Tadaki, Y.; Minaki, S.; Ooshima, T.; Takahashi, H. Contribution of neuropilin-1 in radiation-survived subclones of NSCLC cell line H1299. Curr. Issues Mol. Biol. 2021, 43, 1203–1211.
[18]	Wang, J.Y.; Sheng, Z.Y.; Cai, Y. SIRT6 overexpression inhibits HIF1α expression and its impact on tumor angiogenesis in lung cancer. Int. J. Clin. Exp. Pathol. 2018, 11, 2940–2947.
[19]	Wang, Y.X.; Wang, X.; Guan, Y.; Song, Y.C.; Zhuang, H.Q.; Wang, E.M. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol. Thorac. Cancer. 2020, 11, 1361–1364.
[20]	Song, L.; Han, Y.; Wei, L.Q.; Guo, K.F. The effect of bevacizumab combined with paclitaxel/carboplatin regimen on cell growth factors and tumor markers in advanced non-small cell lung cancer patients. Pract. Drugs Clin. Pract. 2020, 23, 510–513.

贝伐单抗联合放疗方案通过调节VEGF/VEGFR2信号传导治疗NSCLC患者的系统评价

Systematic review: bevacizumab combined with radiotherapy regimen in NSCLC patients, modulating VEGF/VEGFR2 signaling

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 20

相关文章 1

编辑推荐

Metrics

本文评价